Authors

Latest:

Highlighting the Efficacy of VaxEffect With Immune Response to COVID-19 Vaccines

Renold Capocasale and Grant Morgan, PhD, PMP, both of FlowMetric Life Sciences, Inc., discuss the vaccination immune response monitoring platform VaxEffect and its clinical application, as well as potential next steps for immune response tests with other vaccines aside from COVID-19.

Francis Worden, MD

Latest:

Exploring Real-World Evidence Presented at ATA 2023

Medical professionals discuss the recently published real-world evidence presented at the American Thyroid Association 2023 Conference.

Ravi Salgia, MD, PhD, City of Hope Comprehensive Cancer Center

Latest:

Updates in Systemic Therapy for Non-Metastatic Lung Cancer

Hayder M. Saeed, MD, Moffitt Cancer Center

Latest:

Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL

Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.

Noam VanderWalde, MD, MS

Latest:

Dr. VanderWalde on the Importance of Multidisciplinary Care in Rectal Cancer

Noam VanderWalde, MD, MS, discusses the importance of implementing multidisciplinary care for patients with rectal cancer.

Jung-Yun Lee, MD, PhD

Latest:

Dr Lee on Tremelimumab Plus Durvalumab in Ovarian Cancer

Jung-Yun Lee, MD, PhD, discusses primary efficacy and safety findings from the phase 2 KGOG3046/TRU-D trial in patients with newly diagnosed ovarian cancer.

Kami Maddocks, MD, Ohio State University Medical Center

Latest:

Improving Outcomes in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Cedars-Sinai Cancer

Latest:

Missing a Rare Cause of Hereditary Cancer

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.

Niveditha Nerlakanti

Latest:

Nerlakanti on the Role of HDAC Inhibitors in Osteosarcoma

Niveditha Nerlakanti, discusses the investigation of HDAC inhibitors in osteosarcoma.

John D. Shaughnessy, Jr., PhD

Latest:

Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple Myeloma

Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.

Reid Merryman, MD

Latest:

Dr Merryman on the Evolution of MRD Assays in Lymphoma

Reid Merryman, MD, discusses the evolution of minimal residual disease assays in lymphoma.

Tarek H. Mouhieddine, MD

Latest:

Dr. Mouhieddine on Outcomes After Bispecific Antibodies in R/R Multiple Myeloma

Tarek H. Mouhieddine, discusses a study that evaluated outcomes in patients with relapsed/refractory multiple myeloma who progressed on bispecific antibodies.

William P. Harris, MD

Latest:

A Pilot Study of Pembrolizumab in Combination With Y90 Radioembolization in Patients With Poor Prognosis Hepatocellular Carcinoma

William Harris, MD, presents the study design and rationale for HCRN GI15-225, an open-label, single-arm multicenter, pilot study exploring whether using immunotherapy drugs in combination with locoregional therapies for patients with non-metastatic HCC is safe and beneficial, using pembrolizumab every 3 weeks starting 1 week before initial Y90 radioembolization.

Mark M. Awad, MD, PhD

Latest:

Dr Awad on the FDA Approval of Perioperative Nivolumab for Resectable NSCLC

Mark Awad, MD, PhD, discusses the significance of the FDA approval of perioperative nivolumab for patients with resectable NSCLC.

Paul Stewart, PhD

Latest:

Dr Stewart on the Multiomic Landscape of Squamous Cell Lung Cancer

Paul Stewart, PhD, discusses the multiomic landscape of squamous cell lung cancer.

Vikas Kumar Singh, MD

Latest:

Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Sarah Ackroyd, MD, MPH

Latest:

Dr Ackroyd on the Assessment of Time Toxicity in Advanced/Recurrent Endometrial Cancer

Sarah Ackroyd, MD, MPH, discusses the rationale and key results from a study of time-related treatment burden in patients receiving treatment for advanced, recurrent endometrial cancer.

Gabriella Hobbs, MD

Latest:

Future of MF

Experts discuss how treatments, either monotherapy or combination, may impact the treatment landscape for MF and how they might choose among the new agents.

Daniela Sia, PhD

Latest:

Dr. Sia on a Novel Classification System in Intrahepatic Cholangiocarcinoma

Daniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.

Mansi R. Shah, MD

Latest:

Dr Shah on the Effect of IVIG on Infection Risk in R/R Multiple Myeloma

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.